Novo Nordisk’s stock slumps after failed trial — adding to the company’s woes
The Danish healthcare company’s stock slumped on Friday after it announced the Phase 3 trial failure.
Source：MarketWatch
友情提醒：请广大读者理性看待市场信息，切实提高风险意识。站内所有内容仅系市场信息或相关方观点，不构成任何形式投资建议。